Case control study of diffusion tensor imaging in Parkinson's disease

L-L Chan1, H Rumpel, K Yap

  • 1Department of Diagnostic Radiology, Singapore General Hospital, Singapore, Republic of Singapore.

Abstract

Insights

Diffusion tensor imaging (DTI) shows lower fractional anisotropy (FA) in the substantia nigra of Parkinson's disease (PD) patients. This FA value inversely correlates with PD clinical severity, suggesting potential for disease monitoring.

Area of Science:

  • Neuroimaging
  • Neurology
  • Medical Physics

Background:

  • Diffusion Tensor Imaging (DTI) shows promise for diagnosing Parkinson's disease (PD).
  • Previous studies suggest DTI may aid in PD diagnosis.
  • Investigating specific DTI metrics in key brain regions is crucial.

Purpose of the Study:

  • To compare fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values in the basal ganglia and substantia nigra between PD patients and healthy controls.
  • To evaluate the predictive value and clinical utility of these DTI parameters in PD.
  • To determine if DTI metrics can differentiate PD from healthy individuals.

Main Methods:

  • A prospective, case-control study involving 151 subjects (73 PD patients, 78 controls).
  • DTI imaging was performed on all participants.
  • FA and ADC values were extracted from the caudate, putamen, globus pallidus, thalamus, and substantia nigra.

Main Results:

  • A significantly lower FA value was observed in the substantia nigra of PD patients compared to controls (0.403 vs 0.415, p=0.001).
  • No significant differences in FA or ADC values were found in other studied brain structures.
  • PD clinical severity showed an inverse correlation with substantia nigra FA (regression coefficient -0.019).

Conclusions:

  • Lower substantia nigra FA on DTI is a distinguishing feature in Parkinson's disease patients compared to healthy controls.
  • Substantia nigra FA inversely correlates with the clinical severity of PD.
  • Further longitudinal studies are recommended to explore the clinical utility of serial FA measurements for disease progression and therapeutic response monitoring.